Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010
Authors
Keywords
-
Journal
CNS DRUGS
Volume 32, Issue 3, Pages 269-287
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1007/s40263-018-0488-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis
- (2017) Stephanie von Kutzleben et al. IMMUNOLOGY
- Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine
- (2017) Karl B. Alstadhaug et al. JOURNAL OF CLINICAL VIROLOGY
- Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
- (2017) Douglas L. Arnold et al. JOURNAL OF NEUROLOGY
- Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
- (2017) Aiden Haghikia et al. LANCET NEUROLOGY
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
- (2017) Usha Ranganathan et al. Multiple Sclerosis Journal
- Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
- (2017) Nicola De Stefano et al. Multiple Sclerosis Journal
- Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
- (2017) Ralph HB Benedict et al. Multiple Sclerosis Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab
- (2017) Joshua Barton et al. NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
- (2017) David Baker et al. JAMA Neurology
- Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis
- (2017) Usha Ranganathan et al. Multiple Sclerosis Journal
- Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
- (2017) Nicola De Stefano et al. Multiple Sclerosis Journal
- Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study
- (2017) Ralph HB Benedict et al. Multiple Sclerosis Journal
- Pulmonary Nocardia beijingensis infection associated with the use of alemtuzumab in a patient with multiple sclerosis
- (2017) Marwan Sheikh-Taha et al. Multiple Sclerosis Journal
- Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies
- (2017) Nicky Dunn et al. Multiple Sclerosis Journal
- Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
- (2017) Ying Liu et al. Multiple Sclerosis and Related Disorders
- Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis
- (2017) Keh Yann et al. Multiple Sclerosis and Related Disorders
- Classifying PML risk with disease modifying therapies
- (2017) Joseph R. Berger Multiple Sclerosis and Related Disorders
- The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
- (2017) Guillermo Izquierdo et al. PLoS One
- Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
- (2016) Ralf Gold et al. BMC Neurology
- Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing−remitting multiple sclerosis
- (2016) E.-W. Radue et al. EUROPEAN JOURNAL OF NEUROLOGY
- Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
- (2016) Dagmar E. Ehrnhoefer et al. EXPERIMENTAL NEUROLOGY
- Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis
- (2016) Rui Li et al. JOURNAL OF IMMUNOLOGY
- The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl hydrocarbon receptor
- (2016) Johannes Berg et al. JOURNAL OF NEUROIMMUNOLOGY
- In vitro evaluation of physiologically relevant concentrations of teriflunomide on activation and proliferation of primary rodent microglia
- (2016) Tanja Wostradowski et al. Journal of Neuroinflammation
- Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study
- (2016) A. Miclea et al. JOURNAL OF NEUROLOGY
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
- (2016) Irene Cortese et al. NEUROLOGY
- Rituximab in multiple sclerosis
- (2016) Jonatan Salzer et al. NEUROLOGY
- Long-term safety and efficacy of teriflunomide
- (2016) Paul O'Connor et al. NEUROLOGY
- Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor
- (2016) Joel Kaye et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
- (2016) Michael Munsell et al. Patient Preference and Adherence
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis
- (2016) Ludwig Kappos et al. JAMA Neurology
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
- (2016) Ralf Gold et al. Multiple Sclerosis Journal
- The effects of intrathecal rituximab on biomarkers in multiple sclerosis
- (2016) Joanne Topping et al. Multiple Sclerosis and Related Disorders
- Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
- (2016) Giancarlo Comi et al. Multiple Sclerosis and Related Disorders
- Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies
- (2016) Gavin Giovannoni et al. Multiple Sclerosis and Related Disorders
- Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease
- (2016) Marta Garcia-Miralles et al. Scientific Reports
- Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
- (2015) Benedetta Parodi et al. ACTA NEUROPATHOLOGICA
- The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
- (2015) Tjalf Ziemssen et al. BMC Neurology
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- (2015) Samuel F. Hunter et al. CNS DRUGS
- Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
- (2015) Tobias Ruck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis
- (2015) Xavier Montalban et al. JOURNAL OF NEUROLOGY
- Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
- (2015) Jeffrey A Cohen et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Multiple sclerosis—a quiet revolution
- (2015) Richard M. Ransohoff et al. Nature Reviews Neurology
- Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
- (2015) L. Kappos et al. NEUROLOGY
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
- (2015) Dennis J. Nieuwkamp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
- (2015) Thorsten Rosenkranz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
- (2014) Tatiana Plavina et al. ANNALS OF NEUROLOGY
- The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination
- (2014) A Slowik et al. BRITISH JOURNAL OF PHARMACOLOGY
- Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis
- (2014) Muriel Stoppe et al. JOURNAL OF NEUROLOGY
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
- (2014) Thomas P Leist et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- A systematic review of the incidence and prevalence of cancer in multiple sclerosis
- (2014) Ruth Ann Marrie et al. Multiple Sclerosis Journal
- Can we measure long-term treatment effects in multiple sclerosis?
- (2014) Maria Pia Sormani et al. Nature Reviews Neurology
- Laquinimod reduces neuroaxonal injury through inhibiting microglial activation
- (2014) Manoj Kumar Mishra et al. Annals of Clinical and Translational Neurology
- Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
- (2013) Valérie Jolivel et al. BRAIN
- The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro
- (2013) Li Li et al. JOURNAL OF NEUROIMMUNOLOGY
- Fingolimod phosphate promotes the neuroprotective effects of microglia
- (2013) Hiromi Noda et al. JOURNAL OF NEUROIMMUNOLOGY
- Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
- (2013) M. Filippi et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis
- (2013) Krystyna Mitosek-Szewczyk et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study
- (2013) Krzysztof Selmaj et al. LANCET NEUROLOGY
- Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis
- (2013) A. Bar-Or et al. NEUROLOGY
- PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
- (2013) Bob W. van Oosten et al. NEW ENGLAND JOURNAL OF MEDICINE
- PML in a Patient Treated with Fumaric Acid
- (2013) Ummehan Ermis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis
- (2013) Garth E. Ringheim et al. Frontiers in Neurology
- Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia
- (2012) Vikramjeet Singh et al. Journal of Neuroimmune Pharmacology
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine
- (2012) Martin Berghoff et al. LEUKEMIA & LYMPHOMA
- Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years
- (2012) Christian Confavreux et al. Multiple Sclerosis Journal
- Teriflunomide added to interferon- in relapsing multiple sclerosis: A randomized phase II trial
- (2012) M. S. Freedman et al. NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Daclizumab Therapy for Multiple Sclerosis
- (2012) Bibiana Bielekova Neurotherapeutics
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-mediated disease genetics: the shared basis of pathogenesis
- (2012) Chris Cotsapas et al. TRENDS IN IMMUNOLOGY
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- A Novel PEGylated Interferon Beta-1a for Multiple Sclerosis: Safety, Pharmacology, and Biology
- (2011) Xiao Hu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
- (2011) S Cook et al. Multiple Sclerosis Journal
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
- (2010) J. F. Martin et al. JOURNAL OF IMMUNOLOGY
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started